Zurcher Kantonalbank Zurich Cantonalbank Has $4.48 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Royalty Pharma plc (NASDAQ:RPRX) by 11.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 175,652 shares of the biopharmaceutical company’s stock after buying an additional 18,207 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Royalty Pharma were worth $4,481,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Brooklyn Investment Group raised its position in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 876 shares in the last quarter. Allworth Financial LP grew its stake in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 877 shares during the period. Riverview Trust Co lifted its stake in Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,186 shares during the period. Fifth Third Bancorp lifted its stake in Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 997 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 376 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Trading Up 0.3 %

Shares of Royalty Pharma stock opened at $32.77 on Friday. The stock has a market capitalization of $18.89 billion, a PE ratio of 22.60, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a 50 day moving average price of $31.58 and a two-hundred day moving average price of $28.56. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date was Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.